{"id":28998,"date":"2023-02-23T09:26:21","date_gmt":"2023-02-23T14:26:21","guid":{"rendered":"https:\/\/myeloma.ca\/?page_id=28998"},"modified":"2024-10-23T14:18:28","modified_gmt":"2024-10-23T19:18:28","slug":"programme-de-partenariat-visant-le-partage-des-fonds-de-recherche-issus-de-la-marche-myelome-multiple-2024","status":"publish","type":"page","link":"https:\/\/myeloma.ca\/fr\/programme-de-partenariat-visant-le-partage-des-fonds-de-recherche-issus-de-la-marche-myelome-multiple-2024\/","title":{"rendered":"Programme de partenariat visant le partage des fonds de recherche issus de la Marche My\u00e9lome Multiple 2024"},"content":{"rendered":"<div class=\"page-intro-block   block_d912ef22152911f37b75ce31d3f398ca\">\n    <div class=\"container\">\n        <div class=\"left-content\">\n            <div class=\"content\">\n                <h1><strong class='second-font-family is-italic is-italic-fw'>Programme de partenariat visant le partage des fonds de recherche issus<\/strong> de la Marche My\u00e9lome Multiple 2024<\/h1>\n            <\/div>\n            <div class=\"bottom-content\">\n                <div class=\"actions-btns-wrapper\">\n                    <a class=\"print-btn\" href=\"#\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.545\" height=\"14.195\" viewBox=\"0 0 13.545 14.195\"><path d=\"M13.786,9.785v-2.6H7.759v2.6H6.743V6H14.8V9.785Zm-8.77,1.183h0Zm10.142,1.873a.457.457,0,0,0,.356-.177.639.639,0,0,0,0-.828.445.445,0,0,0-.711,0,.639.639,0,0,0,0,.828A.457.457,0,0,0,15.158,12.841Zm-1.371,6.171V15.227H7.759v3.785ZM14.8,20.2H6.743v-3.47H4v-4.85a2.2,2.2,0,0,1,.516-1.489,1.619,1.619,0,0,1,1.278-.6H15.75a1.619,1.619,0,0,1,1.278.6,2.2,2.2,0,0,1,.516,1.489v4.85H14.8Zm1.727-4.653V11.875a.963.963,0,0,0-.22-.651.7.7,0,0,0-.559-.256H5.795a.7.7,0,0,0-.559.256.963.963,0,0,0-.22.651v3.667H6.743v-1.5H14.8v1.5Z\" transform=\"translate(-4 -6)\" fill=\"#3e3a3b\"\/><\/svg>\n                        <span>Imprimer<\/span>\n                    <\/a>\n                    <a class=\"share-btn\" href=\"mailto:?subject=I wanted you to see this!&amp;body=https:\/\/myeloma.ca\/fr\/programme-de-partenariat-visant-le-partage-des-fonds-de-recherche-issus-de-la-marche-myelome-multiple-2024\/\">\n                        <svg height=\"14.195\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M64 96c-17.7 0-32 14.3-32 32v39.9L227.6 311.3c16.9 12.4 39.9 12.4 56.8 0L480 167.9V128c0-17.7-14.3-32-32-32H64zM32 207.6V384c0 17.7 14.3 32 32 32H448c17.7 0 32-14.3 32-32V207.6L303.3 337.1c-28.2 20.6-66.5 20.6-94.6 0L32 207.6zM0 128C0 92.7 28.7 64 64 64H448c35.3 0 64 28.7 64 64V384c0 35.3-28.7 64-64 64H64c-35.3 0-64-28.7-64-64V128z\"\/><\/svg>\n                        <span>Partager<\/span>\n                    <\/a>\n                <\/div>\n                <div class=\"lb-breadcrumb\">\n                    <div class=\"lb-breadcrumbs\"><span><a href=\"https:\/\/myeloma.ca\/fr\/\">Accueil<\/a><\/span><span class=\"lb-breadcrumb-separator\"> | <\/span><\/div>                <\/div>\n            <\/div>\n\n        <\/div>\n    <\/div>\n    <div class=\"page-intro-image-wrapper\">\n\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1637\" height=\"2048\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024.jpg\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024.jpg 1637w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024-240x300.jpg 240w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024-819x1024.jpg 819w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024-768x961.jpg 768w, https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/10\/Hamilton-Niagara-2024-1228x1536.jpg 1228w\" sizes=\"auto, (max-width: 1637px) 100vw, 1637px\" \/>    <\/div>\n        <div class=\"left-content mobile\">\n            <div class=\"bottom-content\">\n                <div class=\"actions-btns-wrapper\">\n                    <a class=\"print-btn\" href=\"#\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.545\" height=\"14.195\" viewBox=\"0 0 13.545 14.195\"><path d=\"M13.786,9.785v-2.6H7.759v2.6H6.743V6H14.8V9.785Zm-8.77,1.183h0Zm10.142,1.873a.457.457,0,0,0,.356-.177.639.639,0,0,0,0-.828.445.445,0,0,0-.711,0,.639.639,0,0,0,0,.828A.457.457,0,0,0,15.158,12.841Zm-1.371,6.171V15.227H7.759v3.785ZM14.8,20.2H6.743v-3.47H4v-4.85a2.2,2.2,0,0,1,.516-1.489,1.619,1.619,0,0,1,1.278-.6H15.75a1.619,1.619,0,0,1,1.278.6,2.2,2.2,0,0,1,.516,1.489v4.85H14.8Zm1.727-4.653V11.875a.963.963,0,0,0-.22-.651.7.7,0,0,0-.559-.256H5.795a.7.7,0,0,0-.559.256.963.963,0,0,0-.22.651v3.667H6.743v-1.5H14.8v1.5Z\" transform=\"translate(-4 -6)\" fill=\"#3e3a3b\"\/><\/svg>\n                        <span>Imprimer<\/span>\n                    <\/a>\n                    <a class=\"share-btn\" href=\"mailto:?subject=I wanted you to see this!&amp;body=https:\/\/myeloma.ca\/fr\/programme-de-partenariat-visant-le-partage-des-fonds-de-recherche-issus-de-la-marche-myelome-multiple-2024\/\">\n                        <svg height=\"14.195\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M64 96c-17.7 0-32 14.3-32 32v39.9L227.6 311.3c16.9 12.4 39.9 12.4 56.8 0L480 167.9V128c0-17.7-14.3-32-32-32H64zM32 207.6V384c0 17.7 14.3 32 32 32H448c17.7 0 32-14.3 32-32V207.6L303.3 337.1c-28.2 20.6-66.5 20.6-94.6 0L32 207.6zM0 128C0 92.7 28.7 64 64 64H448c35.3 0 64 28.7 64 64V384c0 35.3-28.7 64-64 64H64c-35.3 0-64-28.7-64-64V128z\"\/><\/svg>\n                        <span>Partager<\/span>\n                    <\/a>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n\n<div class=\"master-tabs-block   block_2a7aa57770dc7bcc5967121c2be84e30  \">\n    <div class=\"container\">\n        <div class=\"tab-selector-wrapper\">\n        <\/div>\n    <\/div>\n    <div class=\"acf-innerblocks-container\">\n<div data-tab-name=\"Programme de partenariat visant le partage des fonds de recherche issus de la Marche My\u00e9lome Multiple 2024\"\n     id=\"programme-de-partenariat-visant-le-partage-des-fonds-de-recherche-issus-de-la-marche-myelome-multiple-2024\"\n     class=\"master-tab-block   block_571efc0ac6c1724aafd49b97853ade6e\">\n    <div class=\"lm-tab-content\">\n        <div class=\"acf-innerblocks-container\">\n<div class=\" content-1-block   block_e360c8a20a65cd1738073b2d8a83dcd4  \" style=\"padding-top: 5rem;padding-bottom: 5rem;text-align: center;background-color: var(--lb--light-grey);\">\n    <div class=\"container\">\n\t\t        <div class=\"content\">\n\t\t\t<h2>Programme de partenariat visant le partage des fonds de recherche issus de la Marche My\u00e9lome Multiple 2024<\/h2>\n<p>Ce programme offre aux organismes de bienfaisance l\u2019occasion de s\u2019associer \u00e0 My\u00e9lome Canada lors de la MMM la plus pr\u00e8s et de recevoir une bourse de recherche dont le montant peut atteindre jusqu\u2019\u00e0 50 % du montant net des recettes de la MMM!<\/p>\n<p>Nous sommes ravis d\u2019annoncer que quatre des b\u00e9n\u00e9ficiaires du programme en 2023 poursuivront leur participation au programme cette ann\u00e9e, et que trois nouveaux candidats ont \u00e9t\u00e9 s\u00e9lectionn\u00e9s pour rejoindre le programme cette ann\u00e9e.<\/p>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n<div class=\"lb-accordion accordion-block  m-pb5 block_3598810dc88c7d40d9da8a7156b18211 \" style=\"padding-top: 3rem;\">\n    <div class=\"container\">\n        <div class=\"pre-accordion-content\">\n\t\t\t                <h2>Participants au Programme de partenariat visant le partage des fonds de recherche issus de la Marche my\u00e9lome multiple 2024<\/h2>\n\t\t\t\t\t\t        <\/div>\n\t\t            <div class=\"accordion-wrapper\">\n\t\t\t\t                    <div class=\"lb-accordion-single is-openned\">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple de Airdrie<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"display:block\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR\/MultipleMyelomaMarch\/MMM2018?pg=entry&amp;fr_id=1690\">Marche My\u00e9lome Multiple de Airdrie<\/a><\/h3>\n<p>Partenaire : <a href=\"https:\/\/www.ucalgary.ca\/\">Universit\u00e9 de Calgary<\/a><\/p>\n<p>Titre du projet : Sarcopenia in Multiple Myeloma and AL Amyloidosis: Impact of Treatment and Effects of Sarcopenia on Clinical Survival Outcomes, a Pilot Study at the Tom Baker Cancer Centre [Sarcop\u00e9nie chez les personnes atteintes d\u2019un my\u00e9lome multiple ou d\u2019une amylose AL : impact du traitement et effets de la sarcop\u00e9nie sur les r\u00e9sultats cliniques en mati\u00e8re de survie, un projet pilote au Tom Baker Cancer Centre]<\/p>\n<p>Chercheur principal : Dr Victor H. Jimenez-Zepeda, professeur adjoint en m\u00e9decine, Universit\u00e9 de Calgary, clinicien-chercheur, Tom Baker Cancer Centre<\/p>\n<p>Objectifs du projet :<\/p>\n<ul>\n<li>\u00c9valuer l\u2019impact de la sarcop\u00e9nie (perte de la masse musculaire squelettique) sur le taux de survie des patients.<\/li>\n<li>\u00c9tablir si la sarcop\u00e9nie chez les personnes atteintes d\u2019un my\u00e9lome pourrait \u00eatre utilis\u00e9e comme outil d\u2019\u00e9valuation de la fragilit\u00e9.<\/li>\n<li>\u00c9clairer les futurs programmes ax\u00e9s sur la pr\u00e9vention de la progression de la sarcop\u00e9nie.<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t                    <div class=\"lb-accordion-single \">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple d&rsquo;Hamilton-Niagara<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1700&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\" data-link-type=\"web\">Marche My\u00e9lome Multiple d&rsquo;Hamilton-Niagara<\/a><\/h3>\n<p>Partenaire :\u00a0<a href=\"https:\/\/www.hamiltonhealth.ca\/\" target=\"_blank\" rel=\"noopener\">Hamilton Health Sciences Foundation<\/a><\/p>\n<p>Titre du projet : Comparing Outcomes between Progression-Free Survival (PFS) and Time to Next Treatment (TTNT) amongst Patients with Multiple Myeloma [Comparaison des r\u00e9sultats entre la survie sans progression et le temps \u00e9coul\u00e9 jusqu\u2019au prochain traitement chez les patients atteints d\u2019un my\u00e9lome multiple]<\/p>\n<p>\u00c9quipe de recherche : Groupe d\u00e9di\u00e9 au my\u00e9lome au Juravinski Cancer Centre<\/p>\n<p>Objectif du projet :<\/p>\n<ul>\n<li>\u00c9tablir le lien entre le temps \u00e9coul\u00e9 jusqu\u2019au prochain traitement et la survie sans progression chez les personnes atteintes d\u2019un my\u00e9lome afin d\u2019aider les cliniciens \u00e0 prendre des d\u00e9cisions \u00e9clair\u00e9es concernant la s\u00e9lection du traitement, les strat\u00e9gies de gestion pour optimiser les soins aux patients, et la conception de futurs essais cliniques.<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t                    <div class=\"lb-accordion-single \">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple de Kingston<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1703&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\">Marche My\u00e9lome Multiple de Kingston<\/a><\/h3>\n<p>Partenaire :\u00a0<a href=\"https:\/\/www.uhkf.ca\/Home\" target=\"_blank\" rel=\"noopener\">University Hospitals Kingston Foundation<\/a><\/p>\n<p>Titre du projet :Impact of routine Septra prophylaxis in patients receiving an autologous stem cell transplant\u00a0[Impact du traitement prophylactique standard \u00e0 base de Septra chez les patients qui subissent une autogreffe de cellules souches]<\/p>\n<p>Chercheuse principale :Dre Bethany E. Monteith, h\u00e9matologue, Kingston Health Sciences Centre, Universit\u00e9 Queen, Kingston, Ontario<\/p>\n<p>Objectifs du projet :<\/p>\n<ul>\n<li>Am\u00e9liorer la pr\u00e9vention des pneumonies \u00e0 pneumocystis chez les patients subissant une autogreffe de cellules souches en \u00e9valuant l\u2019utilisation standard de deux antibiotiques.<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t                    <div class=\"lb-accordion-single \">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple de la Ville de Qu\u00e9bec<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1712&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\" data-link-type=\"web\">Marche My\u00e9lome Multiple de la Ville de Qu\u00e9bec<\/a><\/h3>\n<p>Partenaire :\u00a0<a href=\"https:\/\/www.chudequebec.ca\/accueil.aspx\" target=\"_blank\" rel=\"noopener\">CHU de Qu\u00e9bec<\/a><\/p>\n<p>Titre du projet : Utilisation des immunoglobulines chez les personnes atteintes de MM recevant un traitement anti-BCMA<\/p>\n<p>Chercheuse principale : Dre Julie C\u00f4t\u00e9, h\u00e9mato-oncologue, Centre hospitalier universitaire de Qu\u00e9bec, ville de Qu\u00e9bec, Qu\u00e9bec<\/p>\n<p>Objectifs du projet :<\/p>\n<ul>\n<li>Aider les cliniciens \u00e0 mieux d\u00e9finir l\u2019utilisation des immunoglobulines dans le traitement d\u2019un my\u00e9lome.<\/li>\n<li>D\u00e9finir la pertinence de l\u2019administration prophylactique d\u2019immunoglobulines en fonction du taux d\u2019IgG.<\/li>\n<li>\u00c9valuer l&rsquo;impact de l&rsquo;administration des Ig sur la qualit\u00e9 de vie des patients.<\/li>\n<li>D\u00e9finir la r\u00e9ponse vaccinale chez cette population de patients.<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t                    <div class=\"lb-accordion-single \">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple de Windsor\/Comt\u00e9 d&rsquo;Essex<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1726&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\" data-link-type=\"web\">Marche My\u00e9lome Multiple de Windsor\/Comt\u00e9 d&rsquo;Essex<\/a><\/h3>\n<p>Partenaire :\u00a0<a href=\"https:\/\/www.uwindsor.ca\/\" target=\"_blank\" rel=\"noopener\">Universit\u00e9 de Windsor<\/a><\/p>\n<p>Titre du projet : Establishing a Multiple Myeloma Drug Screening Platform to Predict Patient Response to Therapy [\u00c9tablissement d\u2019une plateforme d\u2019analyse des m\u00e9dicaments contre le my\u00e9lome multiple pour pr\u00e9dire la r\u00e9ponse du patient au traitement]<\/p>\n<p>Chercheuse principale : Lisa A. Porter,\u00a0Ph. D.; WE-SPARK Health Institute, professeure \u00e9m\u00e9rite, Universit\u00e9 de Windsor, Windsor, Ontario<\/p>\n<p>Objectifs du projet :<\/p>\n<ul>\n<li>\u00c9tablir une plateforme novatrice d\u2019analyse des m\u00e9dicaments pour d\u00e9finir la r\u00e9ponse de personnes atteintes d\u2019un my\u00e9lome \u00e0 certains r\u00e9gimes m\u00e9dicamenteux<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t                    <div class=\"lb-accordion-single \">\n                        <button class=\"lb-accordion-button\"\n                                type=\"button\">\n                            <span>Marche My\u00e9lome Multiple de Vancouver<\/span>\n                        <\/button>\n                        <div class=\"lb-accordion-content\" style=\"\">\n                            <div class=\"lb-accordion-inner-wrapper\">\n\t\t\t\t\t\t\t\t<h3><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1724&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\" data-link-type=\"web\">Marche My\u00e9lome Multiple\u00a0<\/a><a href=\"https:\/\/support.myeloma.ca\/site\/TR?fr_id=1724&amp;pg=entry&amp;s_locale=fr_CA\" target=\"_blank\" rel=\"noopener\" data-link-type=\"web\">de Vancouver<\/a><\/h3>\n<p>Partenaires :\u00a0<a href=\"https:\/\/bccancerfoundation.com\/\" target=\"_blank\" rel=\"noopener\">BC Cancer et\u00a0<\/a><a href=\"https:\/\/bccancerfoundation.com\/\" target=\"_blank\" rel=\"noopener\">BC Cancer Foundation<\/a><\/p>\n<p>Titre du projet : Targeting Replication Stress Tolerance Genes for Myeloma Therapy [Cibler les g\u00e8nes de r\u00e9plication pour le traitement d\u2019un my\u00e9lome]<\/p>\n<p>Chercheur principal : Dr Peter C. Stirling, Ph. D.; laboratoire Terry Fox, BC Cancer, Vancouver, Colombie-Britannique<\/p>\n<p>Objectifs du projet :<\/p>\n<ul>\n<li>Mettre au point de nouveaux inhibiteurs chimiques ciblant Mus81 (une prot\u00e9ine qui agit comme un important m\u00e9canisme de r\u00e9sistance au traitement d\u2019un my\u00e9lome multiple) pour la cr\u00e9ation d\u2019un traitement novateur contre le my\u00e9lome multiple.<\/li>\n<li>\u00c9largir les activit\u00e9s de recherche sur le my\u00e9lome en Colombie-Britannique.<\/li>\n<\/ul>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n\t\t\t\t            <\/div>\n\t\t    <\/div>\n\n<\/div>\n\n<div class=\"cta-1-block m-pt5  block_d4d3dd7254d4683e83add4155ceabab7\" style=\"padding-top: 7rem;padding-bottom: 7rem;\">\n    <div class=\"container\">\n        <div class=\"cta-1-wrapper\">\n            <div class=\"img-wrapper\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"766\" height=\"766\" src=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/Rapport-dimpact-2023-1.png\" class=\"attachment-large size-large\" alt=\"\" \/>            <\/div>\n            <div class=\"content-wrapper\">\n                <h3>En 2023, My\u00e9lome Canada a fi\u00e8rement investi plus de 1,34 million de dollars dans des projets scientifiques et de recherche sur le my\u00e9lome, ici m\u00eame au Canada!<\/h3>\n                            <\/div>\n                            <div class=\"button-wrapper\">\n                    <a class=\"btn btn-empty\" target=\"_blank\" href=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/04\/2023-Rapport-impact_Myelome-Canada_FR.pdf\">T\u00e9l\u00e9charger un exemplaire<\/a>\n                <\/div>\n                    <\/div>\n    <\/div>\n<\/div>\n<\/div>\n    <\/div>\n<\/div>\n<\/div>\n\n            <nav class=\"master-page-anchor-wrapper\">\n            <div class=\"master-page-anchor-header\">\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24.054\" height=\"33.63\" viewBox=\"0 0 24.054 33.63\"><path d=\"M195.2,91.649h16a4.033,4.033,0,0,0,4.029-4.029V69.084a.588.588,0,0,0-.106-.348l-.047-.042-.055-.064L204.1,58.185a.594.594,0,0,0-.42-.165H195.2a4.033,4.033,0,0,0-4.029,4.029V87.62A4.033,4.033,0,0,0,195.2,91.65Zm9.088-31.518,8.715,8.316h-7.633a1.06,1.06,0,0,1-1.06-1.06ZM192.448,62.04h0a2.761,2.761,0,0,1,2.756-2.757h7.816v8.1a2.336,2.336,0,0,0,2.332,2.332h8.6v17.9a2.761,2.761,0,0,1-2.756,2.757h-16a2.761,2.761,0,0,1-2.756-2.757Z\" transform=\"translate(-191.175 -58.02)\" fill=\"#fff\"\/><\/svg>\n                <span>Sur cette page<\/span>\n                <button class=\"master-page-anchor-toggler\" type=\"button\"><i class=\"fa-solid fa-chevrons-left\"><\/i><\/button>\n            <\/div>\n            <div class=\"master-page-anchor-hiddable\">\n                <div class=\"master-page-anchor-navigation\">\n\n                <\/div>\n                <div class=\"master-page-anchor-footer\">\n                    <a href=\"#\" class=\"back-to-top\">\n                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"20\" height=\"20\" viewBox=\"0 0 20 20\"><g transform=\"translate(-2843 426) rotate(-90)\"><circle cx=\"10\" cy=\"10\" r=\"10\" transform=\"translate(406 2843)\" fill=\"#1c596c\"\/><g transform=\"translate(412.135 2845)\"><g transform=\"translate(10.732 7.866) rotate(135)\"><path d=\"M0,4.968V0H4.968\" transform=\"translate(3.389 2.774)\" fill=\"none\" stroke=\"#fff\" stroke-linecap=\"round\" stroke-miterlimit=\"10\" stroke-width=\"1\"\/><\/g><\/g><\/g><\/svg>\n                        <span>Retour en haut<\/span>\n                    <\/a>\n                <\/div>\n            <\/div>\n        <\/nav>\n    \n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":0,"parent":0,"menu_order":19,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-28998","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=28998"}],"version-history":[{"count":6,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28998\/revisions"}],"predecessor-version":[{"id":29005,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/pages\/28998\/revisions\/29005"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=28998"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=28998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}